Table 1A. Description of studies comparing hyaluronic acid with saline solution (n=17).
| Author/year | Patients number | Outcomes measured - Instrument | Adverse effects reported | Molecular weight | Injection number | Follow-up weeks | ||
|---|---|---|---|---|---|---|---|---|
| Hyaluronic Acid | Saline Solution | Pain | Function | |||||
| Altman RD 2004 | 173 | 174 | WOMAC | WOMAC | Yes | High | 1 | 24 |
| Altman RD 2009 | 293 | 295 | WOMAC | WOMAC | Yes | High | 3 | 26 |
| Arden N 2013 | 108 | 110 | WOMAC | WOMAC | Yes | Intermediate | 1 | 6 |
| Baltzer AWA 2008 | 135 | 107 | WOMAC | VAS | Yes | High | 3 | 26 |
| Brandt KD 2001 | 114 | 112 | WOMAC | Yes | Intermediate | 3 | 16 | |
| Chevalier X 2010 | 124 | 129 | WOMAC | WOMAC | Yes | High | 1 | 26 |
| Day R 2004 | 116 | 124 | WOMAC | Yes | High | 5 | 18 | |
| Dougados M 1993 | 55 | 55 | VAS | Lequesne index | Yes | High | 4 | 52 |
| Hangody L 2018 | 150 | 69 | WOMAC | WOMAC | Yes | Intermediate | 1 | 2 |
| Henderson EB 1994 | 45 | 46 | VAS | VAS | Yes | High | 4 | 5 |
| Huang TL 2011 | 98 | 100 | Pain on walking (VAS) | WOMAC | Yes | Low | 5 | 25 |
| Huskisson EC1999 | 50 | 50 | Pain on walking (VAS) | Lequesne index | Yes | High | 5 | 24 |
| Karlsson J 2002 | 88 | 66 | VAS | Lequesne index | Yes | High | 3 | 52 |
| Migliore A 2021 | 347 | 345 | VAS | Lequesne index | Yes | Low/high | 1 | 24 |
| Petterson SC 2019 | 184 | 185 | WOMAC | WOMAC | Yes | High | 1 | 26 |
| Pham T 2004 | 131 | 85 | Global pain (VAS) | Lequesne index | No | Intermediate | 3 | 52 |
| Strand V 2012 | 251 | 128 | WOMAC | Yes | Intermediate | 1 | 1 | |